After conversations with thousands of Scientists, there is stunning lesson in their feedback that every Pharma and Biotech manager should internalize: Collaboration is more valuable than the underlying analysis pipelines.
No matter how great the pipeline, if Scientists can’t explore, interpret and consistently collaborate on a common version of the data then the value invested in the experiment is lost, or simply not realized.
Like dark data, the latent insights in these experiments remain trapped. Interestingly, Pharma and Biotech institutions with a deluge of clinical trial and research data are looking for collaboration tools for their Scientists, not the fundamental analysis pipelines. The implications for oncology research, immunology, drug discovery and disease research are significant.
- Something every Scientist should read: we walked through Collaboration Spaces on ROSALIND, highlighting how it's now possible to collaborate in real-time on genomic data (like Google Docs). Read the post here.
- We've forever transformed Public Data exploration. Follow this link for more information.
- Learn more about the latest capabilities, supported species and levels of access in this post on empowering scientists.